WallStSmart

ICU Medical Inc (ICUI)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 142% more annual revenue ($5.40B vs $2.23B). RMD leads profitability with a 27.5% profit margin vs 0.0%. ICUI appears more attractively valued with a PEG of 0.07. RMD earns a higher WallStSmart Score of 70/100 (B).

ICUI

Hold

47

out of 100

Grade: D+

Growth: 2.0Profit: 4.0Value: 4.7Quality: 6.3
Piotroski: 5/9Altman Z: 1.63

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICUISignificantly Overvalued (-73765.0%)

Margin of Safety

-73765.0%

Fair Value

$0.20

Current Price

$131.38

$131.18 premium

UndervaluedFair: $0.20Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICUI2 strengths · Avg: 9.0/10
PEG RatioValuation
0.0710/10

Growing faster than its price suggests

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

ICUI4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.634/10

Distress zone — elevated risk

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
4.8%3/10

Operating margin of 4.8%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ICUI

The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.07 suggests the stock is reasonably priced for its growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : ICUI

The primary concerns for ICUI are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 4313.3x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

ICUI profiles as a value stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 47/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICU Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?